Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Saracen who wrote (620)	5/9/1998 3:09:00 AM
From: Intrepid1	Respond to of 1185

As to today's market activity, I would be extremely surprised if it were not for the fact that NRT trades on the V.S.E. - the sooner it gets off that horrible exchange the better. Hey Pal, that horrible exchange you refer to financed Nortran through many lean years. Without the venture capital provided by the VSE, the breakthrough drugs being developed by Nortran would only be an idea in a researcher's mind. Silicon Investor has exposed me to that wonderful unregulated American venture(?) capital arena called the OTC BB. Compared to that den of inequity, the VSE, with its State-of-the art trading system, and rigourous disclosure policies, is a much fairer arena for the risk oriented investor. purething

To: Saracen who wrote (620)	5/9/1998 9:13:00 AM
From: Mr. Forthright	Respond to of 1185

The information you had on Hoffman was dead on. You are not on trial here. I am just pointing out the fact that you had information that turned out to be insider information. I am not saying you knew it was (OK guys stop laughing) I am only making it clear that somehow this info ended up on the Internet. As far as recommendations from Gordon and Canaccord are concerned the only impact they will have on the market will come from the promoters promoting the hell out on them. We all know Canaccord and everybody should know that Gordon is no longer the Gordon it used to be. They are desperately looking for business and trying unsuccessfully to become a player in the biotech sector. The fact that Goepel is in the deal gives me more comfort. I would not want to list Nortran on the TSE right now because it will put a cap on the stock price.